Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial

@article{Lau1999AdjuvantIL,
  title={Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial},
  author={W. Y. Lau and T. W. Leung and S K Ho and Michael S Y Chan and D Machin and Joseph T Lau and Atc Chan and Winnie Yeo and Tsk Mok and Sch Yu and Nwy Leung and Pj Johnson},
  journal={The Lancet},
  year={1999},
  volume={353},
  pages={797-801}
}
Adjuvant Intra-arterial Iodine-131-labeled Lipiodol for Resectable Hepatocellular Carcinoma: A Prospective Randomized Trial—Update on 5-Year and 10-Year Survival
TLDR
In patients with HCC, adjuvant intra-arterial 131I-lipiodol after curative liver resection provided survival benefit on the disease-free survival and overall survival, although the difference became statistically insignificant at 8 years after randomization.
Adjuvant Hepatic Intra-arterial Iodine-131-Lipiodol Following Curative Resection of Hepatocellular Carcinoma: A Prospective Randomized Trial
TLDR
The randomized trial provides insufficient evidence to recommend the routine use of 131I-lipiodol in these patients, and the Lipiodol group showed a small, and nonsignificant, improvement over control in RFS and overall survival.
Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis
TLDR
The finding of this study corroborates the current evidence from randomized and nonrandomized trials that adjuvant iodine-131-lipiodol improves disease-free and overall survival in patients with HCC after hepatic resection.
Adjuvant I-131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma
TLDR
Adjuvant I-131 lipiodol improves disease-free survival in patients with HCC and among patients with a recurrence at 2 years, more patients had already experienced such recurrences at 1 year in the control cohort (70 % vs 33 %, p = 0.014).
Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma.
  • K. Ng, R. Niu, D. Morris
  • Medicine
    HPB : the official journal of the International Hepato Pancreato Biliary Association
  • 2008
TLDR
Administration of adjuvant lipiodol I-131 post-curative treatment with surgical resection and/or ablation is associated with good overall survival.
Adjuvant iodine‐131‐labeled lipiodol for prevention of intrahepatic recurrence of hepatocellular carcinoma: Which is the best treatment schedule?
TLDR
The authors' DFS rate is similar to that reported by Boucher et al., confirming the efficacy of this adjuvant therapy, and the measure of the volume of the remnant liver targeted by the I-131-Lip should be included as a variable for results, tailoring the optimal dose for such an adjuant therapy.
Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma.
Adjuvant intra‐arterial injection of iodine‐131–labeled lipiodol after resection of hepatocellular carcinoma
TLDR
A retrospective analysis supports the promising contribution of postoperative injection of 131I‐Lip after resection of HCC and a randomized study including more patients would be necessary to confirm its contribution to therapeutic management.
Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study.
TLDR
This pilot study failed to demonstrate any clinically significant adverse effect of adjuvant therapy by intra-arterial (131)I-lipiodol after curative liver resection for HCC, and suggests a benefit in lowering tumor recurrence.
Systematic Review and Meta-Analysis of Adjuvant I131 Lipiodol after Excision of Hepatocellular Carcinoma
TLDR
There is strong evidence for the use of adjuvant I131 lipiodol, to prolong disease-free and overall survival, up to 5 years after resection, in patients with resected HCC compared with surgery alone.
...
...

References

SHOWING 1-10 OF 18 REFERENCES
Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma.
  • W. Leung, W. Lau, A. Li
  • Medicine
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 1994
TLDR
Treatment with intra-arterial iodine-131-Lipiodol was well tolerated in patients with inoperable hepatocellular carcinoma and produced an objective response of 52% with median survival of 6 mo, and a fractionated dose of 131I-L was feasible and the radiation dose could be escalated safely.
Prospective randomized trial of chemoembolization versus intra‐arterial injection of 131I‐labeled–iodized oil in the treatment of hepatocellular carcinoma
TLDR
In terms of patient survival and tumor response, radioactive 131I‐labeled Lipiodol and chemoembolization were equally effective in the treatment of HCC, but tolerance to 131I-labeledlipiodol was significantly better.
Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma
TLDR
While adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs was effective in improving disease‐free survival, the effect was not satisfactory and further trials of adjUvant chemotherapy are required to improve the surgical survival of hepatocellular carcinoma patients.
Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial.
TLDR
In a group of patients who underwent curative resection of hepatocellular carcinoma, postoperative adjuvant chemotherapy using the present regimen was associated with more frequent extrahepatic recurrences and a worse outcome.
Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma
TLDR
The potential benefits of HCFU on tumour recurrence should be weighed against the risks of adverse reactions in patients with mild liver dysfunction, according to preoperative liver dysfunction.
Intrahepatic Recurrence After Resection of Hepatocellular Carcinoma Complicating Cirrhosis
TLDR
It is indicated that liver transplantation might be envisaged for the treatment of cirrhotic patients with resectable hepatocellular carcinoma with high recurrence rate after resection, even with careful evaluation of tumor extension.
Superselective intra-arterial radiometabolic therapy with I-131 lipiodol in hepatocellular carcinoma.
TLDR
Superselective arterial radioembolization with I-131 lipiodol is a useful palliative approach to inoperable hepatocarcinoma, providing long-term local control without severe complications in the progression of cirrhosis.
Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients
TLDR
Results in survival are much improved over the past reports, and the differences are probably a result of earlier diagnosis and frequent hepatic resection, probably due to the coexistent advanced cirrhosis.
Postoperative Recurrence of Hepatocellular Carcinoma
TLDR
There was a significant negative correlation between the size of primary tumor and time until recurrence; the larger the primary tumor, the shorter the time until Recurrence.
...
...